Should Invesco NASDAQ Next Gen 100 ETF (QQQJ) Be on Your Investing Radar?
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 26 2024
0mins
Should l Buy ALNY?
Source: NASDAQ.COM
Invesco NASDAQ Next Gen 100 ETF Overview: The Invesco NASDAQ Next Gen 100 ETF (QQQJ) is a passively managed fund launched in 2020, focusing on large-cap growth stocks with a low expense ratio of 0.15%. It has approximately $667.28 million in assets and primarily invests in the Information Technology sector.
Performance and Comparison: QQQJ has shown a year-to-date increase of about 10.86% and a 22.11% rise over the past year, while also offering diversification across 104 holdings. It is ranked as a "Hold" by Zacks, and investors may consider similar ETFs like Vanguard Growth ETF (VUG) and Invesco QQQ (QQQ) for additional options.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALNY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALNY
Wall Street analysts forecast ALNY stock price to rise
17 Analyst Rating
14 Buy
3 Hold
0 Sell
Strong Buy
Current: 308.480
Low
351.00
Averages
479.53
High
580.00
Current: 308.480
Low
351.00
Averages
479.53
High
580.00
About ALNY
Alnylam Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of hereditary transthyretin-mediated amyloidosis (hATTR) with polyneuropathy in adults; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Fitusiran, Zilebesiran, Elebsiran, Mivelsiran and ALN-HTT02. It is developing Cemdisiran to treat complement-mediated diseases.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Alnylam Pharmaceuticals Reports Mixed Q4 and 2025 Results
- Significant Revenue Growth: Alnylam Pharmaceuticals reported nearly $1.1 billion in Q4 2025 revenue, nearly doubling year-over-year, indicating strong performance in the biotech sector, yet falling short of the $1.15 billion analyst forecast.
- Substantial Net Income Increase: The company’s non-GAAP net income soared to $169.8 million, or $1.25 per share, a significant rise from just over $8 million a year ago, surpassing the analyst estimate of $1.19 per share, reflecting a marked improvement in profitability.
- Key Product Sales Driver: The net sales of Amvuttra accounted for 83% of the company’s net product revenue, with the drug receiving FDA approval in March 2025 for treating transthyretin amyloid cardiomyopathy, driving robust sales and demonstrating strong market demand.
- Cautious Future Outlook: Alnylam projects total revenue for 2026 to be between $5.3 billion and $5.8 billion, with the analyst consensus at $5.55 billion, but did not provide a net income forecast, indicating uncertainty regarding future profitability.
See More
Alnylam Pharmaceuticals Reports Strong 2025 Earnings Despite Stock Decline
- Significant Revenue Growth: Alnylam Pharmaceuticals reported nearly $1.1 billion in revenue for Q4 and full-year 2025, nearly doubling year-over-year, although it fell short of the $1.15 billion analyst forecast, indicating strong performance in the biotech sector.
- Substantial Net Income Increase: The company's non-GAAP net income surged to approximately $169.8 million, or $1.25 per share, compared to just over $8 million last year, surpassing the consensus estimate of $1.19 per share, reflecting improved profitability.
- Amvuttra Revenue Driver: The net sales of Amvuttra accounted for 83% of Alnylam's net product revenue, highlighting the strong market demand for this drug in treating transthyretin amyloid cardiomyopathy, which is crucial for the company's growth.
- Optimistic Future Outlook: Alnylam is guiding for total revenue between $5.3 billion and $5.8 billion for 2026, with the analyst consensus at $5.55 billion, indicating confidence in the sales potential of its new indication despite not providing a net income forecast.
See More
ALNYLAM PHARMACEUTICALS INC PROJECTS FY TOTAL NET PRODUCT REVENUE BETWEEN $4.9 BILLION AND $5.3 BILLION
- Financial Overview: The total net product revenue for the company is projected to be between $4.9 billion and $5.3 billion.
- Market Expectations: This revenue forecast indicates a positive outlook for the company's performance in the pharmaceutical sector.
See More
Alnylam Pharmaceuticals Q4 Earnings Miss Expectations
- Disappointing Earnings: Alnylam Pharmaceuticals reported a Q4 non-GAAP EPS of $1.25, missing expectations by $0.25, indicating pressure on profitability that could affect investor confidence.
- Weak Revenue Growth: Despite an 83.8% year-over-year revenue increase to $1.09 billion, the figure fell short of expectations by $70 million, suggesting that market demand did not meet anticipated levels, potentially impacting future market strategies.
- 2026 Financial Guidance: The company projects total TTR net product revenues between $4.4 billion and $4.7 billion for 2026, with rare disease net product revenues expected between $500 million and $600 million, reflecting cautious optimism for future growth while remaining attentive to market dynamics.
- R&D and SG&A Expenses: Non-GAAP R&D and SG&A expenses are anticipated to be between $2.7 billion and $2.8 billion, demonstrating the company's ongoing commitment to R&D investment, although this may exert pressure on profit margins.
See More
Alnylam Pharmaceuticals to Announce Q4 Earnings on February 12
- Earnings Announcement: Alnylam Pharmaceuticals is set to release its Q4 2023 earnings on February 12 before market open, with consensus EPS estimated at $1.50 and revenue expected to reach $1.16 billion, reflecting a significant 95.6% year-over-year growth, which could have a substantial impact on the company's stock performance.
- Performance Expectations: Over the past two years, Alnylam has beaten EPS and revenue estimates 75% of the time, indicating a stable market performance; however, in the last three months, EPS estimates have seen three upward revisions and five downward adjustments, while revenue estimates experienced four upward revisions and ten downward adjustments, highlighting market uncertainty regarding future performance.
- Market Dynamics: Alnylam will exit the Nasdaq 100 alongside Lululemon and Biogen, with companies like Alnylam and Seagate being added, which may affect investor attention and the company's market positioning.
- Debt Management Strategy: Alnylam announced a partial repurchase of convertible notes due in 2027, a move that not only helps optimize its capital structure but also potentially boosts investor confidence in the company's financial health, thereby positively influencing its stock price.
See More
Alnylam Pharmaceuticals Q4 2025 Earnings Outlook
- Earnings Expectations: Alnylam anticipates total Q4 2025 revenue of $1.16 billion with adjusted earnings per share of $1.50, indicating sustained growth potential in the biotech sector.
- Amvuttra Sales Surge: In Q3 2025, Amvuttra's sales skyrocketed by 162% year-over-year, primarily driven by rapid adoption in the transthyretin cardiac amyloidosis (ATTR-CM) indication, which is expected to boost Q4 performance.
- Market Performance: Although Alnylam's market share remains limited in international markets, particularly in Q4, stronger growth is anticipated in Germany and Japan in 2026, reflecting the company's strategic positioning in global markets.
- Pipeline Updates: Alnylam is expected to provide updates on its pipeline progress in the upcoming earnings report, including the initiation of a Phase 3 study for hereditary ATTR with polyneuropathy and a Phase 2 trial for Alzheimer's disease, showcasing ongoing R&D advancements.
See More
Alnylam Pharmaceuticals Reports Mixed Q4 and 2025 Results
- Significant Revenue Growth: Alnylam Pharmaceuticals reported nearly $1.1 billion in Q4 2025 revenue, nearly doubling year-over-year, indicating strong performance in the biotech sector, yet falling short of the $1.15 billion analyst forecast.
- Substantial Net Income Increase: The company’s non-GAAP net income soared to $169.8 million, or $1.25 per share, a significant rise from just over $8 million a year ago, surpassing the analyst estimate of $1.19 per share, reflecting a marked improvement in profitability.
- Key Product Sales Driver: The net sales of Amvuttra accounted for 83% of the company’s net product revenue, with the drug receiving FDA approval in March 2025 for treating transthyretin amyloid cardiomyopathy, driving robust sales and demonstrating strong market demand.
- Cautious Future Outlook: Alnylam projects total revenue for 2026 to be between $5.3 billion and $5.8 billion, with the analyst consensus at $5.55 billion, but did not provide a net income forecast, indicating uncertainty regarding future profitability.
See More
Alnylam Pharmaceuticals Reports Strong 2025 Earnings Despite Stock Decline
- Significant Revenue Growth: Alnylam Pharmaceuticals reported nearly $1.1 billion in revenue for Q4 and full-year 2025, nearly doubling year-over-year, although it fell short of the $1.15 billion analyst forecast, indicating strong performance in the biotech sector.
- Substantial Net Income Increase: The company's non-GAAP net income surged to approximately $169.8 million, or $1.25 per share, compared to just over $8 million last year, surpassing the consensus estimate of $1.19 per share, reflecting improved profitability.
- Amvuttra Revenue Driver: The net sales of Amvuttra accounted for 83% of Alnylam's net product revenue, highlighting the strong market demand for this drug in treating transthyretin amyloid cardiomyopathy, which is crucial for the company's growth.
- Optimistic Future Outlook: Alnylam is guiding for total revenue between $5.3 billion and $5.8 billion for 2026, with the analyst consensus at $5.55 billion, indicating confidence in the sales potential of its new indication despite not providing a net income forecast.
See More
ALNYLAM PHARMACEUTICALS INC PROJECTS FY TOTAL NET PRODUCT REVENUE BETWEEN $4.9 BILLION AND $5.3 BILLION
- Financial Overview: The total net product revenue for the company is projected to be between $4.9 billion and $5.3 billion.
- Market Expectations: This revenue forecast indicates a positive outlook for the company's performance in the pharmaceutical sector.
See More
Alnylam Pharmaceuticals Q4 Earnings Miss Expectations
- Disappointing Earnings: Alnylam Pharmaceuticals reported a Q4 non-GAAP EPS of $1.25, missing expectations by $0.25, indicating pressure on profitability that could affect investor confidence.
- Weak Revenue Growth: Despite an 83.8% year-over-year revenue increase to $1.09 billion, the figure fell short of expectations by $70 million, suggesting that market demand did not meet anticipated levels, potentially impacting future market strategies.
- 2026 Financial Guidance: The company projects total TTR net product revenues between $4.4 billion and $4.7 billion for 2026, with rare disease net product revenues expected between $500 million and $600 million, reflecting cautious optimism for future growth while remaining attentive to market dynamics.
- R&D and SG&A Expenses: Non-GAAP R&D and SG&A expenses are anticipated to be between $2.7 billion and $2.8 billion, demonstrating the company's ongoing commitment to R&D investment, although this may exert pressure on profit margins.
See More
Alnylam Pharmaceuticals to Announce Q4 Earnings on February 12
- Earnings Announcement: Alnylam Pharmaceuticals is set to release its Q4 2023 earnings on February 12 before market open, with consensus EPS estimated at $1.50 and revenue expected to reach $1.16 billion, reflecting a significant 95.6% year-over-year growth, which could have a substantial impact on the company's stock performance.
- Performance Expectations: Over the past two years, Alnylam has beaten EPS and revenue estimates 75% of the time, indicating a stable market performance; however, in the last three months, EPS estimates have seen three upward revisions and five downward adjustments, while revenue estimates experienced four upward revisions and ten downward adjustments, highlighting market uncertainty regarding future performance.
- Market Dynamics: Alnylam will exit the Nasdaq 100 alongside Lululemon and Biogen, with companies like Alnylam and Seagate being added, which may affect investor attention and the company's market positioning.
- Debt Management Strategy: Alnylam announced a partial repurchase of convertible notes due in 2027, a move that not only helps optimize its capital structure but also potentially boosts investor confidence in the company's financial health, thereby positively influencing its stock price.
See More
Alnylam Pharmaceuticals Q4 2025 Earnings Outlook
- Earnings Expectations: Alnylam anticipates total Q4 2025 revenue of $1.16 billion with adjusted earnings per share of $1.50, indicating sustained growth potential in the biotech sector.
- Amvuttra Sales Surge: In Q3 2025, Amvuttra's sales skyrocketed by 162% year-over-year, primarily driven by rapid adoption in the transthyretin cardiac amyloidosis (ATTR-CM) indication, which is expected to boost Q4 performance.
- Market Performance: Although Alnylam's market share remains limited in international markets, particularly in Q4, stronger growth is anticipated in Germany and Japan in 2026, reflecting the company's strategic positioning in global markets.
- Pipeline Updates: Alnylam is expected to provide updates on its pipeline progress in the upcoming earnings report, including the initiation of a Phase 3 study for hereditary ATTR with polyneuropathy and a Phase 2 trial for Alzheimer's disease, showcasing ongoing R&D advancements.
See More
